Last Updated : March 19, 2025
Details
Generic Name:
mirvetuximab soravtansine
Project Status:
Active
Therapeutic Area:
Epithelial ovarian, fallopian tube, or primary peritoneal cancer
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0394-000
Call for patient/clinician input closed:
Tumour Type:
Gynecology
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with folate receptor-alpha (FR) positive*, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
For the treatment of adult patients with folate receptor-alpha (FRα) positive*, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | January 17, 2025 |
|---|---|
| Call for patient/clinician input closed | March 18, 2025 |
| Submission received | March 03, 2025 |
| Submission accepted | March 18, 2025 |
| Review initiated | March 19, 2025 |
| Draft CADTH review report(s) provided to sponsor for comment | June 13, 2025 |
| Deadline for sponsors comments | June 24, 2025 |
| CADTH review report(s) and responses to comments provided to sponsor | July 31, 2025 |
| Expert committee meeting (initial) | August 13, 2025 |
| Draft recommendation issued to sponsor | August 25, 2025 To August 27, 2025 |
| Draft recommendation posted for stakeholder feedback | September 04, 2025 |
| End of feedback period | September 18, 2025 |
Last Updated : March 19, 2025